|
Age, years
|
58.40 ± 9.40
|
59.54 ± 9.23
|
58.94 ± 9.46
|
56.67 ± 9.28
|
< 0.001
|
|
Male, n (%)
|
1218 (77.4)
|
423 (80.6)
|
406 (76.2)
|
389 (75.4)
|
0.097
|
|
BMI, kg/m2
|
25.96 ± 3.23
|
25.28 ± 3.06
|
26.04 ± 3.18
|
26.57 ± 3.32
|
< 0.001
|
|
LVEF, %
|
62.17 ± 7.01
|
62.55 ± 6.61
|
61.93 ± 7.14
|
62.04 ± 7.26
|
0.312
|
|
Diagnosis, n (%)
| | | | |
0.061
|
|
UA
|
1334 (84.8)
|
459 (87.4)
|
452 (84.8)
|
423(82.0)
| |
|
NSTEMI
|
116 (7.4)
|
33 (6.3)
|
44 (8.3)
|
39 (7.6)
| |
|
STEMI
|
124 (7.9)
|
33 (6.3)
|
37 (6.9)
|
54 (10.5)
| |
|
Medical history, n (%)
|
|
Current smoking
|
556 (35.3)
|
173 (33.0)
|
184 (34.5)
|
199 (38.6)
|
0.030
|
|
Hypertension
|
1016 (64.5)
|
313 (59.6)
|
344 (64.5)
|
359 (69.6)
|
0.004
|
|
Hypercholesteraemia
|
610 (38.8)
|
192 (36.6)
|
198 (37.1)
|
220 (42.6)
|
0.086
|
|
Diabetes mellitus
|
544 (34.6)
|
111 (21.1)
|
173 (32.5)
|
260 (50.4)
|
< 0.001
|
|
Previous stroke
|
127 (8.1)
|
46 (8.8)
|
43 (8.1)
|
38 (7.4)
|
0.710
|
|
Previous PCI
|
289 (18.4)
|
95 (18.1)
|
108 (20.3)
|
86 (16.7)
|
0.317
|
|
Laboratory tests
|
|
Hs-CRP, mg/L
|
1.43 (0.56, 3.97)
|
0.93 (0.40, 3.11)
|
1.44 (0.59, 3.78)
|
1.89 (0.82, 4.58)
|
< 0.001
|
|
eGFR, mL/min/1.73 m2
|
96.54 ± 14.72
|
96.71 ± 13.93
|
96.56 ± 14.46
|
96.34 ± 15.78
|
0.921
|
|
Uric acid, umol/L
|
345.49 ± 84.69
|
332.35 ± 74.62
|
345.42 ± 81.91
|
358.92 ± 94.61
|
< 0.001
|
|
Homocysteine, umol/L
|
12.50 (9.70, 16.10)
|
12.80 (9.80, 16.55)
|
12.70 (9.85, 16.1)
|
12.00 (9.50, 15.68)
|
0.095
|
|
FBG, mmol/L
|
6.57 ± 2.31
|
5.50 ± 0.97
|
6.19 ± 1.54
|
8.04 ± 3.06
|
< 0.001
|
|
Triglycerides, mmol/L
|
1.40 (1.02, 1.98)
|
0.90 ± 0.26
|
1.47 ± 0.33
|
2.47 ± 0.88
|
< 0.001
|
|
TC, mmol/L
|
4.11 ± 1.07
|
3.75 ± 0.92
|
4.09 ± 0.97
|
4.50 ± 1.17
|
< 0.001
|
|
HDL-C, mmol/L
|
1.07 ± 0.24
|
1.15 ± 0.26
|
1.06 ± 0.23
|
0.99 ± 0.21
|
< 0.001
|
|
LDL-C, mmol/L
|
2.47 ± 0.89
|
2.24 ± 0.82
|
2.51 ± 0.86
|
2.67 ± 0.93
|
< 0.001
|
|
Angiography
|
|
LM disease, n (%)
|
139 (8.8)
|
53 (10.1)
|
50 (9.4)
|
36 (7.0)
|
0.179
|
|
Multivessel/LM disease, n (%)
|
1195 (75.9)
|
384 (73.1)
|
423 (79.4)
|
388 (75.2)
|
0.055
|
|
Chronic total occlusion, n (%)
|
367 (23.3)
|
104 (19.8)
|
130 (24.4)
|
133 (25.8)
|
0.058
|
|
SYNTAX score
|
13.93 ± 7.42
|
13.72 ± 7.83
|
14.36 ± 7.43
|
13.70 ± 6.97
|
0.253
|
|
Intervention
|
|
Target vessel, n (%)
|
|
LM
|
78 (5.0)
|
30 (5.7)
|
30 (5.6)
|
18 (3.5)
|
0.175
|
|
LAD
|
889 (56.5)
|
304 (57.9)
|
296 (55.5)
|
289 (56.0)
|
0.714
|
|
LCX
|
434 (27.6)
|
125 (23.8)
|
151 (28.3)
|
158 (30.7)
|
0.042
|
|
RCA
|
640 (40.7)
|
214 (40.8)
|
217 (40.7)
|
209 (40.5)
|
0.996
|
|
Intracoronary imagine, n (%)
|
100 (6.4)
|
40 (7.6)
|
31 (5.8)
|
29 (5.6)
|
0.343
|
|
DES-sirolimus, n (%)
|
849 (53.9)
|
288 (54.9)
|
281 (52.7)
|
280 (54.3)
|
0.772
|
|
DES-zotarolimus, n (%)
|
345 (21.9)
|
127 (24.2)
|
117 (22.0)
|
101 (19.6)
|
0.198
|
|
DES-everolimus, n (%)
|
597 (37.9)
|
187 (35.6)
|
210 (39.4)
|
200 (38.8)
|
0.400
|
|
Number of stent, /patients
|
2.00 (1.00, 2.00)
|
1.00 (1.00, 2.00)
|
2.00 (1.00, 2.00)
|
1.00 (1.00, 2.00)
|
0.227
|
|
Multiple stents (n ≥ 2)
|
789 (50.1)
|
256 (48.8)
|
280 (52.5)
|
253 (49.0)
|
0.392
|
|
Length of stents, mm/patients
|
36 (23, 61)
|
36 (21, 58.50)
|
38 (23, 62)
|
35 (23, 63.75)
|
0.223
|
|
Minimal stent diameter, mm
|
2.84 ± 0.46
|
2.88 ± 0.47
|
2.83 ± 0.46
|
2.82 ± 0.46
|
0.105
|
|
Medications at discharge, n (%)
|
|
Aspirin
|
1574 (100.0)
|
525 (100.0)
|
533 (100.0)
|
516 (100.0)
|
> 0.99
|
|
Clopidogrel/Ticagrelor
|
1574 (100.0)
|
525 (100.0)
|
533 (100.0)
|
516 (100.0)
|
> 0.99
|
|
Statin
|
1570 (99.7)
|
523 (99.6)
|
532 (99.8)
|
515 (99.8)
|
0.779
|
|
β-block
|
1088 (69.2)
|
337(64.2)
|
378 (71.1)
|
373 (72.3)
|
0.009
|
|
ACEI/ARB
|
722 (45.9)
|
206 (39.2)
|
250 (46.9)
|
266 (51.6)
|
< 0.001
|
|
Insulin
|
174 (11.1)
|
37 (7.0)
|
52 (9.8)
|
85 (16.5)
|
< 0.001
|
|
Other hypoglycemic agents
|
431 (27.4)
|
86 (16.4)
|
133 (25.0)
|
212 (41.1)
|
< 0.001
|
